Tuesday's After-Hours Movers: Vertex Pharmaceuticals, Orexigen Therapeutics And More
TubeMogul Inc. (NASDAQ: TUBE) gained 13 percent to $17.50 in late trading Tuesday after the enterprise software company for digital branding posted first quarter earnings and raised its guidance.
Hortonworks Inc. (NASDAQ: HDP) rose 10 percent to $24 in the extended session. The data management platform provider said first quarter revenue increased 167 percent to $22.8 million.
New Relic Inc. (NYSE: NEWR) traded up 8 percent to $35.50 after the bell. The cloud-base analytics platform provider said fiscal fourth quarter revenue grew 68 percent.
Opower Inc. (NYSE: OPWR) ticked up 5 percent to $11.25. The provider of cloud-based software for the utility industry said quarterly revenue gained 17 percent.
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) gained more than 5 percent to $132.89 on news that a regulatory advisory committee recommended approval of its cystic fibrosis treatment called Orkambi. An FDA decision is expected by July 5.
Zillow Group Inc. (NASDAQ: Z) ticked up about 2 percent following the bell to $99.60. The company posted first quarter pro forma revenue growth of 35 percent and reiterated its full-year outlook.
Orexigen Therapeutics Inc. (NASDAQ: OREX) tumbled more than 13 percent to $5.15. The company terminated a cardiovascular outcomes trial of its anti-obesity drug Contravene, from which interim results were inadvertently released earlier this year. The trial is not being terminated because of a finding of superiority or harm. An additional trial is expected to be completed in 2020.
Star Bulk Carriers Corp. (NASDAQ: SBLK) declined 10 percent to $3.40 after the Greek maritime shipper announced a $150 million public offering.
Vivint Solar Inc. (NYSE: VSLR) declined about 8 percent to $13.80. The residential solar company posted first quarter results and an outlook.
Exar Corp. (NYSE: EXAR) lost about 5 percent, trading at $9.55, after the integrated circuit maker said its market softened in the recent quarter and it hired financial advisors to review alternatives.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.